Showing 6911-6920 of 8179 results for "".
- FDA Approves Galderma's Restylane Kysse for Lip Augmentation and Upper Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-kysse-for-lip-augmentation-and-upper-perioral-rhytids-1/2460374/The FDA has approved Galderma'a Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is the first hyaluronic acid (HA) filler specifically indicated for the lips using XpresHAn Technology globally referred to as the OB
- Urgent: CMS Extends MIPS Extreme and Uncontrollable Circumstances Exception Application Until 4/30/2020https://practicaldermatology.com/news/urgent-cms-extends-mips-extreme-and-uncontrollable-circumstances-exception-application/2460369/The Centers for Medicare & Medicaid Services (CMS) re-opened the 2019 MIPS Extreme and Uncontrollable Circumstances Exception Application to individuals, groups, and virtual groups, including those who have already submitted data, due to the 2019 Novel Coronavirus (COVID-19) pandemi
- COVID-19 By the Numbers: April 28 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-28-edition/2460365/The CDC now lists nine potential symptoms of COVID-19, though cough and shortness of breath or difficulty breathing remain hallmarks of the disease. CDC says individuals may have COVID-19 if they experience these two symptoms plus at least two of the following: Fever
- Prescriber’s Choice Launches “PC Direct” and “PC Delivers”https://practicaldermatology.com/news/prescribers-choice-launches-pc-direct-and-pc-delivers/2460362/Two new options from Prescriber’s Choice enable physicians to prescribe and ship medicines directly to patients for the treatment of dozens of dermatologic conditions. The ability to ship Prescriber’s Choice medicines to patients is an alternative to existing in-office dispensing to s
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- COVID-19 By the Numbers: April 21 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-21-edition/2460357/More than 300,000 Americans could die if all social distancing measures are abandoned, according to documents obtained by the Center for Public Inte
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop n
- Finacea Foam Back in Pharmacies: LEO Pharmahttps://practicaldermatology.com/news/finacea-foam-back-in-pharmacies-leo-pharma/2460347/After a shortage due to production delays, Finacea®(azelaic acid) Foam, 15% is now available, LEO Pharma says. Finacea Foam is the first and only prescription foam FDA approved for the treatment of rosacea. It is a light water-based (hydrophilic) foam that is alcohol-free and fragrance free.<
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir